Client Result
Carlyle and SK Capital to Acquire bluebird bio
March.07.2025
bluebird bio announced it will be acquired in a take private transaction by Beacon Parent Holdings, collaborating with Carlyle Group and SK Capital.
Client Result
Weights & Biases to be Acquired by CoreWeave
March.06.2025
Weights & Biases, a leading AI developer platform, announced that it has reached an agreement to be acquired by CoreWeave, the AI Hyperscaler™.
Client Result
Combatting Rare Pediatric Disease: Ipsen to Sell Priority Review Voucher
October.10.2024
Ipsen has agreed to sell its rare pediatric disease priority review voucher to a large global pharmaceutical company for $158 million.
Client Result
Advancing Effective Mental Healthcare: Grow Therapy Raises $88 Million
April.11.2024
Grow Therapy, a provider-centric tech company improving access to high-quality mental healthcare, has closed an $88 million funding round.
Client Result
Ultrafast 3D Printing: Orrick Advises Nexa3D on its Acquisition of Essentium
February.09.2024
Nexa3D, the ultrafast 3D printing leader, has acquired Essentium. Orrick represented Nexa3D.
Client Result
Machine-Learning-Powered Generative Biology: Mirae Asset Group Joins $273M Funding Round for Generate:Biomedicines
September.15.2023
Mirae Asset Global Investments has participated in a $273 million in Series C financing for Generate:Biomedicines.
Client Result
Eli Lilly to Acquire Versanis Bio in up to $1.925 Billion Deal With Potential Implications for Treating Obesity
July.20.2023
Eli Lilly and Company and Versanis Bio have announced a definitive agreement for Lilly to pay up to $1.925 billion in cash to acquire Versanis.
Client Result
Aptean Acquisition of TOTALogistix Enhances its Ability to Help Companies Optimize Logistics
June.13.2023
Orrick advised Aptean in its acquisition of TOTALogistix.
Client Result
Orrick Advises COVA Acquisition on $3.82 Billion SPAC Merger with ECARX
December.20.2022
The merged company will be publicly listed on Nasdaq under the ticker symbol "ECX" with an expected pro forma equity value of approximately $3.82 ...
Client Result
Orrick Advises Kineta on Merger with Yumanity Therapeutics
June.06.2022
Under the definitive agreement, Kineta will become a wholly-owned subsidiary of Yumanity in an all-stock transaction.
Client Result
Orrick Advises Fisker on Launch of $350 Million At-the-Market Equity Program
May.24.2022
Orrick advised Fisker in connection with the establishment of its at-the-market equity program.
Client Result
Orrick Advised Catalyst Biosciences on $60 Million Sale of Complement Portfolio
May.24.2022
Orrick advised South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc.